Anti-tumor necrosis factor VNAR single domains reduce lethality and regulate underlying inflammatory response in a murine model of endotoxic shock
- Rafael Bojalil†1, 2,
- María Teresa Mata-González†3,
- Fausto Sánchez-Muñoz1,
- Yepci Yee1,
- Iván Argueta1,
- Lucía Bolaños1,
- Luis Manuel Amezcua-Guerra1,
- Tanya Amanda Camacho-Villegas4, 5,
- Edna Sánchez-Castrejón5,
- Walter Jakob García-Ubbelohde3,
- Alexei Fedorovish Licea-Navarro5,
- Ricardo Márquez-Velasco1, 6Email author and
- Jorge Fernando Paniagua-Solís3, 7
© Bojalil et al.; licensee BioMed Central Ltd. 2013
Received: 3 September 2012
Accepted: 11 March 2013
Published: 2 April 2013
In sepsis, tumor necrosis factor (TNF) is the key factor triggering respiratory burst, tissue injury and disseminated coagulation. Anti-TNF strategies based on monoclonal antibodies or F(ab’)2 fragments have been used in sepsis with contradictory results. Immunoglobulin new antigen receptors (IgNAR) are a unique subset of antibodies consisting of five constant (CNAR) and one variable domains (VNAR). VNAR domains are the smallest, naturally occurring, antibody-based immune recognition units, having potential use as therapy.
Our aim was to explore the impact of an anti-TNF VNAR on survival in an experimental model of endotoxic shock. Also, mRNA expression and serum protein of several inflammatory molecules were measured.
Endotoxic shock was induced by lipopolysaccharide (LPS) in male Balb/c mice. Animals were treated with anti-TNF VNAR domains, F(ab’)2 antibody fragments, or saline solution 15 minutes before, 2 h and 24 h after lethal dose100 (LD100) LPS administration. TNF blockade with either VNAR domains or F(ab’)2 fragments were associated with lower mortality (60% and 75%, respectively) compared to LD100. Challenge with LPS induced significant production of serum TNF and interleukins -10 and -6 at 3 h. After that, significant reduction of IL-6 at 24 h (vs 3 h) was shown only in the VNAR group. Nitrites level also increased in response to LPS.
In liver, TNF and IL-10 mRNA expression showed a pro-inflammatory imbalance in response to LPS. Blocking TNF was associated with a shift towards an anti-inflammatory status; however, polarization was more pronounced in animals receiving F(ab’)2 fragments than in those with VNAR therapy. With regard to IL-6, gene expression was increased at 3 h in all groups. TNF blockade was associated with rapid and sustained suppression of IL-6 expression, even more evident in the VNAR group. Finally, expression of inducible-nitric oxide synthase (iNOS) increased in response to LPS at 3 h, but this was decreased at 24 h only in the anti-TNF VNAR group.
Anti-TNF VNAR single domains improved survival in a murine model of endotoxic shock. Protection was associated with regulation in the TNF/IL-10 balance, attenuation of IL-6 and iNOS gene expression in the liver as well as decreased serum IL-6 concentration.
KeywordsEndotoxic shock Sepsis Anti-TNF VNAR Inflammation
Sepsis is a life-threatening condition which results from an exacerbated inflammatory process caused by complex interactions between the innate immune system and either bacterial sources of infection or their circulating antigens, mainly lipopolysaccharides (LPS). Circulating LPS is engaged by Toll-like receptor 4 (TLR4) on the surface of monocytes and macrophages, which in turn result in cell activation and early production of large amounts of inflammatory cytokines [1, 2]. Tumor necrosis factor (TNF) plays a key role in sepsis due to its ability to trigger respiratory burst and nitric oxide production while diminishing peripheral vascular resistance, leading to disseminated intravascular coagulation and multiple organ failure [3–5].
Elucidation of pathophysiological events that underlie sepsis has led to the development of molecules targeting these pathways. Major strategies to block TNF have included the use of anti-TNF monoclonal antibodies, soluble TNF receptors with IgG chimeric protein, and anti-TNF F(ab’)2 fragments [6–8]. Interestingly, both the effectiveness and usefulness of each anti-TNF strategy varies among studies, often being conflictive and even contradictory. This could be partly the result of the intensity of TNF blockade as well as the tissue penetration achieved by each type of molecule.
Immunoglobulin new antigen receptors (IgNAR) are a unique subset of antibodies found in sharks. It consists of homodimers of polypeptide chains, each comprising a single variable (VNAR) and five constant (CNAR) domains. Single VNAR domains are candidates to be the smallest, naturally occurring, antibody-based immune recognition units . Moreover, VNAR domains have been suggested as a highly effective set of molecules capable to access antigenic sites rarely targeted by conventional antibody-based strategies, positioning them as attractive candidates for therapy [10–12]. Thus, we explored the survival of mice in an experimental model of endotoxic shock, after treatment with a VNAR single domain directed against TNF.
Efficacy of VNAR on survival
Inflammatory markers in sera
TNF/IL-10 ratio was considered to represent antagonistic inflammatory responses in endotoxic shock . While a predominance of anti-inflammatory response driven by IL-10 was steadily observed in the F(ab’)2 group from 3 h to 48 h of surveillance, VNAR treated animals showed a pro-inflammatory response characterized by high TNF and low IL-10 serum concentrations.
Serum concentrations (mean ± standard error) of IL-6 were similar at 3 h in all endotoxemic shock groups (Figure 2, panel C) and significantly different to those of normal group (p < 0.001). F(ab’)2 group showed a gradual decrement (from 13392 ± 1749 to 7919 ± 1991 pg/mL at 24 h), while this decline was abrupt in the VNAR group (from 13288 ± 1793 to 783 ± 703 pg/mL; p < 0.05). IL-6 levels were undetectable at 48 h in all groups.
Liver mRNA quantification
Relative mRNA expression of TNF and IL-10 in liver increased at 3 h as a result of LPS administration (Figure 2, panels D and E, **p < 0.01, ***p < 0.001). However while LD100 of LPS induced a predominant pro-inflammatory response, TNF blockade with either molecule was associated with an anti-inflammatory predominance. However, subtle differences in the TNF/IL-10 balance were found, because polarization to an anti-inflammatory status was more pronounced in the animals receiving F(ab’)2 fragments than in those with VNAR therapy.
Interleukin-6 gene expression in liver increased early (3 h) after LPS challenge in all groups (Figure 2, panel F). TNF blockade was associated with rapid (24 h) and sustained (48 h) suppression of IL-6 mRNA expression; however, the intensity was different according to the anti-TNF strategy used. Indeed, VNAR therapy showed to be more effective than F(ab’)2 to suppress IL-6 mRNA expression at 24 h (1.33 versus 34.27; p < 0.05) and 48 h (5.69 versus 24.20 p < 0.05) after induction of endotoxemia.
Finally, expression of mRNA inducible-nitric oxide synthase (iNOS) in liver was similar between all groups at 3 h (Figure 3, panel B) (from 5811 ± 1422 to 8560 ± 1603); at 24 h both anti-TNF schemes strikingly decreased iNOS mRNA expression, but only in VNAR group this reduction was found to be statistically significant.
VNAR domains are promissory antibody-based molecules because of their particular features such as low molecular weight and size, resistance to gastric pH and long CDR3 loop. VNAR domains are currently used to neutralize bioactive molecules and viruses [11, 14], as well as to perform in vitro diagnostic assays . Herein, we present the first study aimed to report an anti-TNF VNAR that improves survival in a murine model of endotoxic shock. Our results support a role for TNF bioactivity blockade in the treatment of sepsis, and suggest that different anti-TNF strategies may reach different survival rates through differentially attenuating inflammatory mechanisms.
In the present study, anti-TNF administration was not associated with early (3 h) depletion of serum TNF levels; on the contrary, TNF was detected in sera from animals in all groups. In contrast, serum TNF declined to almost undetectable levels at 24 h and 48 h after administration of either F(ab’)2 fragments or VNAR domains. These results are opposed to others studies showing that treatments with anti-TNF antibodies early reduce serum TNF concentration [15, 16]. A possible explanation is based on the molecular weight and bioavailability of each molecule. In this context, while conventional murine monoclonal IgG antibodies (159 kD) have a serum half-life of 25 days , mean serum half-life of smaller molecules is reduced, possibly as a result of improved clearance. Indeed, F(ab’)2 fragments (100 kD) show a mean serum half-life of 2 hrs , and VNAR (14 KD) single domains as little as 3 min to 1.5 hrs .
The liver plays key physiological roles including blood filtering of toxins as well as inactivation and clearing of bacterial antigens and products . Thus, the liver is a site in which early inflammatory changes in sepsis can be assessed by measuring the expression of several pro- and anti-inflammatory molecules . Due to the size of VNAR single domains, they may arrive to the liver and, possibly, deeply penetrate in hepatic tissue , which ultimately may result in the attenuation of inflammatory response. In our study, untreated animals with endotoxic shock showed an intense pro-inflammatory response featured by high expression of TNF and low expression of IL-10 in liver, while anti-TNF treated groups were characterized by an anti-inflammatory response featured by high expression of IL-10 and low expression of TNF.
The protective role of IL-10 in animal sepsis may be due to its antagonistic effect on the production and overall functioning of TNF [23–25]. In this way, it has been demonstrated that neutralization of IL-10 in septic animals and the induction of endotoxemic shock in IL-10 knockout animals are associated with increased tissue injury [26, 27] and higher serum levels of interferon-γ and TNF [28, 29]. In our study, a lower anti-inflammatory TNF/IL-10 ratio was associated with the administration of VNAR domains compared to F(ab’)2 fragments. This could be associated with the trend for higher survival observed in the group on VNAR therapy. In support to this notion, we have previously described that regulation in the IL-1β/IL-10 balance is associated with protection against lethality in a sepsis model of cecal ligation and puncture [7, 30]. The presence of similar results in different models of sepsis further supports that modulation of inflammation would tame tissue injury mechanisms, while full blockade of an inflammatory pathway would facilitate polarization of the immune response in either systemic inflammatory response syndrome or its counterpart, compensatory anti-inflammatory response syndrome .
Tumor necrosis factor directly influences the production of IL-6 and iNOS [31–33] and it is conceivable that its attenuation could have regulated both gene expression and serum concentration of IL-6 and nitric oxide (NO) in our experiments. For example, it has been reported that the administration of anti-IL-6 antibodies improves survival in sepsis [34, 35]; while TNF blockade inhibits hepatic expression of iNOS and nitrotyrosine in mice with endotoxic shock .
In addition, protection of liver seems to be critical to obtain beneficial outcomes in sepsis. In a recent study performed in rats with polymicrobial sepsis, treatment with hyperoncotic albumin attenuates hepatic injury in association with reduced plasma levels of IL-1β, IL-6, liver enzymes, and O2- concentrations . These results support anti-TNF VNAR domains as an alternative approach in the treatment of sepsis, due to its attenuating effects on the inflammatory response showed in liver; however these must be further studied in more aggressive models such as the polymicrobial sepsis induced by cecal ligation and puncture. Related to the latter study, a recent rat gut model of indomethacin-induced jejunoileitis showed that anti-TNF-α monoclonal antibody reduced iNOS expression and IL-1 beta, the latter two thought to be key mediators of inflammatory bowel disease .
Anti-TNF VNAR single domains are a novel strategy useful to improve survival in a murine model of endotoxic shock, with efficacy similar to that observed with the use of anti-TNF F(ab’)2 fragments. Protection against lethality was associated with regulation in the TNF/IL-10 inflammatory balance, attenuation of IL-6 and iNOS liver expression, and decreased IL-6 serum concentration.
Isolation of anti-TNF VNAR single domains
Isolation of anti-TNF VNAR domains was performed as previously described [39, 40]. In brief, a specimen of horn shark Heterodontus francisci was repeatedly immunized (intravenous route) with human recombinant TNF (Peprotech Inc, Connecticut USA). After immunization, RNA from the spleen was obtained and used to amplify variable genes through polymerase chain reaction (PCR), and libraries were generated. A specific clone was obtained by phage display technique and cultures of Pichia pastoris were used to express it, in accordance with the Easy Select Pichia Expression Manual (Invitrogen, USA); pPICZαAvector and X-33 strain were used. vNAR single domains were isolated and purified in the Centro de Investigación Científica y de Educación Superior de Ensenada (Mexico).
Induction of murine endotoxic shock and treatment schedule
Protocol was approved by the ethics committee at the Instituto Nacional de Cardiología Ignacio Chávez (Protocol number 11–726). Male Balb/c mice, classified as an inbred based on 20 or more successive brother-sister matings , 8–12 weeks old were housed under standard laboratory conditions with food and water ad libitum (UAM-Xochimilco, Mexico City, Mexico). Initially, independent experiments were performed to investigate the Lethal Dose 100 (LD100), which was found to be 20 mg/kg of LPS serotype O55:B5 (Sigma-Aldrich, St. Louis, MO) diluted in 100 μL 0.9% saline solution, administered by intraperitoneal (IP) injection in a single dose. Similarly, a pilot assay was performed to investigate the dose of anti-TNF VNAR domains useful to improve survival in the murine model of endotoxemic shock, doses of 0.01, 0.1 and 1 mg/kg of VNAR anti-TNF were tested, the latter dose was the only one that induced protection. To compare active treatment with anti-TNF VNAR domains, we used anti-TNF F(ab’)2 antibody fragments (Laboratorios Silanes, Mexico City, MX). We used the same dose of the latter antibody (1 mg/kg) since it had previously shown protective activity in the cecal ligation and puncture model.
Mice (20 per group) were allocated in groups to receive (A) LD100 LPS in 100 μL 0.9% saline solution by IP injection, these mice also received 100 μl of 0.9% saline solution by IP injection, 15 minutes before as well as at 2 and 24 h after LD100 LPS was administrated; (B) 1 mg/kg anti-TNF VNAR domains diluted in 100 μl 0.9% saline solution by IP injection, 15 minutes before as well as at 2 and 24h after LD100 LPS was administrated; (C) 1 mg/kg anti-TNF F(ab’)2 antibody fragments diluted in 100 μL 0.9% saline solution by IP injection administrated in a similar time schedule than VNAR domains; (D) 100 μl 0.9% saline solution IP in the same time schedule as the other groups; these mice received neither LPS nor anti-TNF treatment.
Measurement of serum markers
Using another batch of mice, blood from 10 anesthetized animals for each group and time was obtained by cardiac puncture at 3, 24 and 48 h after induction of endotoxemia. Serum TNF, IL-6 and IL-10 concentrations were measured by enzyme-linked immunosorbent assays (R&D Systems, Minneapolis, MN). In addition, non-hemolysed serum was used to measure nitrites (NO2-) by means of a Griess reagent system (Promega Corp, Madison, USA). All assays were performed according to manufacturer.
Liver mRNA quantification by RT-qPCR
Ten animals per group and time were sacrificed at 3, 24 or 48 h after LPS administration and liver tissue was immediately frozen and stored at -70°C. One-hundred milligrams from each liver were homogenized using Tri Reagent (Sigma-Aldrich). RNA integrity was assessed by agarose gel stained with ethidium bromide and purity was determined by spectrophotometer (260/280 > 1.8); 2 micrograms of total RNA were retro-transcribed using random primers in a 20 μl reaction with the Transcriptor First cDNA synthesis kit (Roche Applied Science, Indianapolis, USA). One microliter of cDNA was amplified by qPCR using the LightCycler 2.0 with LightCyclerTaqMan Master Mix (Roche) and PCR primers in combination with LNA hydrolysis probes designed with the probe finder software v. 2.45 from the Universal Probe Library Mouse Set (Roche).
PCR was performed using the following primers: Inducible nitric oxide synthase 2 (NM_010927.3), forward 5′-gggctgtcacggagatca-′3, reverse 5′-ccatgatggtcacattctgc-′3; IL-6 (NM_031168.1), forward 5′-gctaccaaactggatataatcagga-′3, reverse 5′-ccaggtagctatggtactccagaa-′3; IL-10 (NM_007393.3), forward 5′-cagagccacatgctcctaga-′3, reverse 5′-gtccagctggtcctttgttt-′3; TNF (NM_013693.2), forward 5′-tcttctcattcctgcttgtgg-′3, reverse 5′-ggtctgggccatagaactga-′3; and Actb (NM_007393.3), forward 5′-ctaaggccaaccgtgaaaag-′3, reverse 5′-accagaggcatacagggaca-′3 as a constitutive gen.
Relative expression of each gene was calculated according to 2-ΔΔCt. Assays were tested for linearity and reproducibility (variation coefficients <10%).
Results are expressed as proportions or mean ± standard deviation. Comparison of survival curves was performed using the Mantel-Haenzel log-rank test. Differences between two independent groups were calculated by Mann–Whitney tests, while those comparisons including more than two groups were performed by the Kruskal-Wallis test (Dunn’s post test). All analyses were 2-tailed and a p < 0.05 value was used for significance. The GraphPad Prism v 4.02 statistical software (GraphPad Inc, San Diego, CA) was used.
Immunoglobulin new antigen receptors
Inducible nitric oxide synthase
Lethal dose 100
Toll-like receptor 4
Tumor necrosis factor
Single variable domain.
This study was supported by Laboratorios Silanes, S. A. de C. V. and Fundación Mexicana para la Salud A. C. Mexico City, Mexico.
- López-Bojórquez LN, Zentella-Dehesa A, Reyes-Terán G: Molecular mechanisms involved in the pathogenesis of septic shock. Arch Med Res. 2004, 35: 465-479. 10.1016/j.arcmed.2004.07.006.View ArticlePubMedGoogle Scholar
- Tetta C, Fonsato V, Ronco C, Camussi G: Recent insights into pathogenesis of severe sepsis. Crit Care Resusc. 2005, 7: 32-39.PubMedGoogle Scholar
- Macdonald J, Galley HF, Webster NR: Oxidative stress gene expression in sepsis. Br J Anaesth. 2003, 90: 221-232. 10.1093/bja/aeg034.View ArticlePubMedGoogle Scholar
- Fujii E, Yoshioka T, Ishida H, Irie K, Muraki T: Evaluation of iNOS- dependent and independent mechanisms of the microvascular permeability change induced by lipopolysaccharide. Br J Pharmacol. 2000, 130: 90-94. 10.1038/sj.bjp.0703277.PubMed CentralView ArticlePubMedGoogle Scholar
- Zeerleder S, Hack E, Wuillemin WA: Disseminated intravascular coagulation in sepsis. Chest. 2005, 128: 2864-2875. 10.1378/chest.128.4.2864.View ArticlePubMedGoogle Scholar
- Remick D, Manohar P, Bolgos G, Rodríguez J, Moldawer L, Wollenberg G: Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock. 1995, 4: 89-95. 10.1097/00024382-199508000-00002.View ArticlePubMedGoogle Scholar
- Márquez-Velasco R, Bojalil R, Buelna A, Flores-Guzmán F, Estevez-Ramirez J, Laguna J: Anti-tumor necrosis factor alpha F(ab’)2 antibody fragments protect in murine polymicrobial sepsis: concentration and early intervention are fundamental to the outcome. Inflamm Res. 2006, 5: 378-384.View ArticleGoogle Scholar
- Karima R, Matsumoto S, Higashi H, Matsushima K: The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today. 1999, 5: 123-132. 10.1016/S1357-4310(98)01430-0.View ArticlePubMedGoogle Scholar
- Juarez K, Dubberke G, Lugo P, Koch-Nolte F, Buck F, Haag F, Licea A: Monoclonal antibodies for the identification and purification of vNAR domains and IgNAR immunoglobulins from the horn shark Heterodontus francisci. Hybridoma (Larchmt). 2011, 30: 323-329. 10.1089/hyb.2011.0010.View ArticleGoogle Scholar
- Nuttall S, Humberstone K, Krishnan U, Carmichael J, Doughty L, Hattarki M: Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins. 2004, 55: 187-197. 10.1002/prot.20005.View ArticlePubMedGoogle Scholar
- Henderson KA, Strelstov VA, Coley AM, Dolezal O, Hudson PJ, Batchelor AH: Structure of an VNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malaria strain recognition. Structure. 2007, 15: 1452-1466. 10.1016/j.str.2007.09.011.View ArticlePubMedGoogle Scholar
- Liu JL, Anderson GP, Delehanty JB, Baumann R, Hayhurst A, Goldman ER: Selection of cholera toxin specific VNAR single- domain antibodies from a naïve shark library. Selection of cholera toxin specific VNAR single-domain antibodies from a naive shark library. Mol Immunol. 2007, 44: 1775-83. 10.1016/j.molimm.2006.07.299.View ArticlePubMedGoogle Scholar
- Mengozzi M, Ghezzi P: Cytokine down-regulation in endotoxin tolerance. Eur Cytokine Netw. 1993, 4: 89-98.PubMedGoogle Scholar
- Walsh R, Nuttall S, Revill P, Colledge D, Cabuang L, Soppe S, Dolezal O: Targeting the hepatitis B virus precore antigen with a novel VNAR single variable domain intrabody. Virology. 2011, 41: 132-141.View ArticleGoogle Scholar
- Evans T, Carpenter A, Silva A, Cohen J: Differentitial effects of monoclonal antibodies to tumor necrosis factor and gamma interferon on induction of hepatic nitric oxide synthase in experimental gram-negative sepsis. Infect Immun. 1992, 60: 4133-4139.PubMed CentralPubMedGoogle Scholar
- Karzai W, Cui X, Mehlton B, Straube E, Hartung T, Gerstenberger E: Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats. Anesthesiology. 2003, 99: 81-89. 10.1097/00000542-200307000-00016.View ArticlePubMedGoogle Scholar
- Wang W, Wang EQ, Balthasar JP: Monoclonal Antibody Pharmacokinetics and Pharmacodynamics. Clin Pharmacol Ther. 2008, 84: 548-558. 10.1038/clpt.2008.170.View ArticlePubMedGoogle Scholar
- Holliger P, Hudson P: Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005, 23: 1126-1136. 10.1038/nbt1142.View ArticlePubMedGoogle Scholar
- Cortez-Retamozo V, Lauwereys M, Hassanzadeh G, Gobert M, Conrath K, Muyldermans S: Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. 2002, 98: 456-462. 10.1002/ijc.10212.View ArticlePubMedGoogle Scholar
- Dhainaut JF, Marin N, Mignon A, Vinsonneau A: Hepatic response to sepsis: Interactions between coagulation and inflammatory processes. Crit Care Med. 2001, 29: S42-S47.View ArticlePubMedGoogle Scholar
- Wu RQ, Xu YX, Song XH, Chen LJ, Meng XJ: Adhesion molecule and proinflammatory cytokine gene expression in hepatic sinusoidal endothelial cells following cecal ligation and puncture. World J Gastroenterol. 2001, 7: 128-130.PubMedGoogle Scholar
- Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M: Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol. 2009, 198: 157-174. 10.1007/s00430-009-0116-7.PubMed CentralView ArticlePubMedGoogle Scholar
- Gérard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A: Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med. 1993, 177: 547-550. 10.1084/jem.177.2.547.View ArticlePubMedGoogle Scholar
- Kato T, Murata A, Ishida H, Toda H, Tanaka N, Hayashida H: Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob Agents Chemother. 1995, 39: 1336-1340. 10.1128/AAC.39.6.1336.PubMed CentralView ArticlePubMedGoogle Scholar
- Latifi SQ, O’Riordan MA, Levine AD: Interleukin 10 controls the onset of irreversible septic shock. Infect Immun. 2002, 70: 4441-4446. 10.1128/IAI.70.8.4441-4446.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Lu J, Sadri N, Schneider RJ: Endotoxic shock in AUF1 knockout mice mediated by failure to degrade proinflammatory cytokine mRNAs. Genes Dev. 2006, 20: 3174-3184. 10.1101/gad.1467606.PubMed CentralView ArticlePubMedGoogle Scholar
- ter Steege JC, van de Ven WC, Forget P, Buurman WA: Regulation of lipopolysaccharide-induced NO synthase expression in the major organs in a mouse model. The roles of endogenous interferon-γ, tumor necrosis factor-α and interleukin-10. Eur Cytokine Netw. 2000, 11: 39-46.PubMedGoogle Scholar
- Berg DJ, Kühn R, Rajewsky K, Müller W, Menon S, Davidson N: Interleukin-10 is a central regulator of the response to LPS in murine models models of endotoxic shock and the Schwartzman reaction but not endotoxin tolerance. J Clin Invest. 1995, 96: 2339-2347. 10.1172/JCI118290.PubMed CentralView ArticlePubMedGoogle Scholar
- Marchant A, Bruyns C, Vandenabeele P, Ducarme M, Gérard C, Delvaux A: Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol. 1994, 24: 1167-1171. 10.1002/eji.1830240524.View ArticlePubMedGoogle Scholar
- Márquez-Velasco R, Martínez-Velázquez AX, Amezcua-Guerra LM, Flores-Guzmán F, Díaz-Quiñonez A, Massó F: Enhanced survival from CLP-induced sepsis following late administration of low doses of anti-IFNγF(ab’)2 antibody fragments. Inflamm Res. 2011, 60: 947-953. 10.1007/s00011-011-0355-0.View ArticlePubMedGoogle Scholar
- Cesaris P, Starace D, Riccioli A, Padula F, Filipinu A, Ziparo E: Tumor necrosis factor-α induces interleukin-6 production and integrin ligand expression by distinct transduction pathways. J Biol Chem. 1998, 273: 7566-7571. 10.1074/jbc.273.13.7566.View ArticlePubMedGoogle Scholar
- Vincent JL, Zhang H, Szabo C, Preiser JC: Effects of nitric oxide in septic shock. Am J Respir Crit Care Med. 2000, 161: 1781-1785. 10.1164/ajrccm.161.6.9812004.View ArticlePubMedGoogle Scholar
- Bekker L, Freeman S, Murray PJ, Ryffel B, Kaplan G: TNF-α controls intracellular Mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol. 2001, 166: 6728-6734.View ArticlePubMedGoogle Scholar
- Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV: Protective effects of IL-6 blockade in sepsis are liked to reduced C5a receptor expression. J Immunol. 2003, 170: 503-507.View ArticlePubMedGoogle Scholar
- Liang B, Gardner D, Griswold D, Song X: Protection against lipopolysaccharide-induced death by an anti-IL-6 monoclonal antibody. Am J Immunol. 2007, 3: 4-9.View ArticleGoogle Scholar
- Morikawa A, Kato Y, Sugiyama T, Koide N, Chakravortty D, Yoshida T, Yokochi T: Role of nitric oxide in lipopolysaccharide-induced hepatic injury in D-galactosamine-sensitized mice as an experimental endotoxic shock model. Infect Immun. 1999, 67: 1018-1024.PubMed CentralPubMedGoogle Scholar
- Tsao CM, Huang HC, Chen ZF, Liaw WJ, Lue WM, Chen A, Chen SJ WUCC: Beneficial effects of hyperoncotic albumin on liver injury and survival in peritonitis-induced sepsis rats. Shock. 2011, 35: 210-216. 10.1097/SHK.0b013e3181f229f8.View ArticlePubMedGoogle Scholar
- Nandi J, Saud B, Zinkievich JM, Yang ZJ, Levine RA: TNF-alpha modulate iNOS expression in an experimental rat model of indomethacin-induced jejunoileitis. Mol Cell Biochem. 2010, 336: 17-24. 10.1007/s11010-009-0259-2.View ArticlePubMedGoogle Scholar
- Minsky A, Summers RG, Knowles JR: Secretion of beta lactamase into the periplasm of Escherichia coli: evidence for a distinct release step associated with a conformational change. Proc Natl Acad Sci USA. 1986, 83: 4180-4184. 10.1073/pnas.83.12.4180.PubMed CentralView ArticlePubMedGoogle Scholar
- Barbas CF, Burton DR, Scott JK: Phage Display: A Laboratory Manual. 2001, New York: Cold Spring Harbor Laboratory Press, Cold Spring HarborGoogle Scholar
- Hilgers J, van Nie R, Ivanyi D, Hilkens J, Michalides R, de Moes J, Poort-Keesom R, Kroezen V, von Deimling O, Kominami R, Holmes R: Genetic differences in BALB/c sublines. Curr Top Microbiol Immunol. 1985, 122: 19-30. 10.1007/978-3-642-70740-7_3.PubMedGoogle Scholar